Literature DB >> 21763260

Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Yongchun Wang1, Alan K Meeker, Jeanne Kowalski, Hua-Ling Tsai, Helina Somervell, Christopher Heaphy, Lauren E Sangenario, Nijaguna Prasad, William H Westra, Martha A Zeiger, Christopher B Umbricht.   

Abstract

Telomere dysfunction and aberrant telomerase expression play important roles in tumorigenesis. In thyroid tumors, three possibly inhibitory splice variants of the active full-length isoform of human telomerase reverse transcriptase (hTERT) may be expressed. These variants might regulate telomerase activity and telomere length because it is the fraction of the full-length isoform, rather than the total transcript level, that correlates with enzymatic activity. Telomerase reactivation may be critical in the early stages of tumorigenesis, when progressive telomere shortening may be limiting cell viability. The aim of this study was to investigate the relationship between telomere length and hTERT splice variant expression patterns in benign and well-differentiated malignant thyroid tumors. Telomere lengths of 61 thyroid tumors were examined by fluorescence in situ hybridization, comparing tumors with adjacent normal thyroid tissue on the same slide. Expression patterns of hTERT splice variants were evaluated by quantitative and nested RT-PCR. Telomere length was inversely correlated with percentage of full-length hTERT expression rather than with total hTERT expression levels. Short telomeres and high fractions of full-length hTERT transcripts were associated with follicular and papillary thyroid carcinomas, whereas long telomeres and low levels of full-length hTERT were associated with benign thyroid nodules. Intermediate levels of full-length hTERT and telomere length were found in follicular variant of papillary thyroid carcinomas and follicular adenomas.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763260      PMCID: PMC3157225          DOI: 10.1016/j.ajpath.2011.05.056

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  67 in total

1.  Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma.

Authors:  Andrew A Renshaw; Edwin W Gould
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.

Authors:  Clare L Fasching; Kylie Bower; Roger R Reddel
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

3.  Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications.

Authors:  P Matthews; C J Jones; J Skinner; M Haughton; C de Micco; D Wynford-Thomas
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

Review 4.  Evaluation and management of the solid thyroid nodule.

Authors:  H B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  1995-12       Impact factor: 4.741

Review 5.  Telomeres, telomerase and malignant transformation.

Authors:  Oliver G Opitz
Journal:  Curr Mol Med       Date:  2005-03       Impact factor: 2.222

6.  Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.

Authors:  Miaw-Jene Liou; Err-Cheng Chan; Jen-Der Lin; Feng-Hsuan Liu; Tzu-Chieh Chao
Journal:  Cancer Lett       Date:  2003-03-10       Impact factor: 8.679

7.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

8.  Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings.

Authors:  H Gharib; J R Goellner; A R Zinsmeister; C S Grant; J A Van Heerden
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

9.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

10.  The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression.

Authors:  Andrea Proctor Subhawong; Christopher M Heaphy; Pedram Argani; Yuko Konishi; Nina Kouprina; Hind Nassar; Russell Vang; Alan K Meeker
Journal:  Mod Pathol       Date:  2009-09-04       Impact factor: 7.842

View more
  14 in total

Review 1.  Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review).

Authors:  Brittany A Avin; Christopher B Umbricht; Martha A Zeiger
Journal:  Int J Oncol       Date:  2016-10-20       Impact factor: 5.650

2.  Microenvironmental regulation of telomerase isoforms in human embryonic stem cells.

Authors:  Lida Radan; Chris S Hughes; Jonathan H Teichroeb; Flora M Vieira Zamora; Michael Jewer; Lynne-Marie Postovit; Dean Harvey Betts
Journal:  Stem Cells Dev       Date:  2014-06-17       Impact factor: 3.272

3.  Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.

Authors:  Brittany A McKelvey; Timothy Gilpatrick; Yongchun Wang; Winston Timp; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2020-05-04       Impact factor: 6.568

4.  Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study.

Authors:  Aline Rangel-Pozzo; Tinuccia Dettori; Daniela Virginia Frau; Federica Etzi; John Gartner; Garbor Fisher; Roberta Vanni; Sabine Mai; Paola Caria
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

5.  Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.

Authors:  Li-Jie Ma; Xiao-Ying Wang; Meng Duan; Long-Zi Liu; Jie-Yi Shi; Liang-Qing Dong; Liu-Xiao Yang; Zhi-Chao Wang; Zhen-Bin Ding; Ai-Wu Ke; Ya Cao; Xiao-Ming Zhang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  J Pathol       Date:  2017-10-13       Impact factor: 7.996

6.  Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Authors:  S-K Leivonen; M Taskinen; A Cervera; M-L Karjalainen-Lindsberg; J Delabie; H Holte; R Lehtonen; S Hautaniemi; S Leppä
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

Review 7.  Alternative Splicing of hTERT Pre-mRNA: A Potential Strategy for the Regulation of Telomerase Activity.

Authors:  Xuewen Liu; Yuchuan Wang; Guangming Chang; Feng Wang; Fei Wang; Xin Geng
Journal:  Int J Mol Sci       Date:  2017-03-07       Impact factor: 5.923

8.  Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.

Authors:  Brittany A Avin; Yongchun Wang; Timothy Gilpatrick; Rachael E Workman; Isac Lee; Winston Timp; Christopher B Umbricht; Martha A Zeiger
Journal:  Genes Chromosomes Cancer       Date:  2019-02-10       Impact factor: 4.263

Review 9.  Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Authors:  Yoshiko Maida; Kenkichi Masutomi
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

10.  Expression Pattern of Alternative Splicing Variants of Human Telomerase Reverse Transcriptase (hTERT) in Cancer Cell Lines Was not Associated with the Origin of the Cells.

Authors:  Mohsen Khosravi-Maharlooei; Mansooreh Jaberipour; Ahmad Hosseini Tashnizi; Armin Attar; Fatemeh Amirmoezi; Mojtaba Habibagahi
Journal:  Int J Mol Cell Med       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.